- <![CDATA[Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy]]><![CDATA[Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.]]>onclive · 2mo ago↗ source
- [Podcast] Closing the Distance in Cancer Care<figure><div><img src="https://imgproxy.divecdn.com/dY7Wm0PCubv9b4fcIzKfj5an0kT_H96KaWu7liYNw1Y/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9NY0tlc3Nvbl9Qb2RjYXN0XzEzNDZ4NzI5X…BioPharma Dive · 2mo ago↗ source
- <![CDATA[Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer]]><![CDATA[Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.]]>